Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel

Pteridines

Volumn 17, Issue 4, 2006, Pages 107-114

  Melichar, Bohuslav ^a,b   Solichova, Dagmar ^a   Melicharova, Karolina ^a   Cermanova, Melanie ^a   Urminska, Hana ^a   Ryska, Ales ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anemia; Breast cancer; Neopterin; Paclitaxel; Thrombocytosis

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; GRANISETRON; HEMOGLOBIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FEMALE; HEMOGLOBIN ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOSIS; URINALYSIS;

EID: 33947405728     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2006.17.4.107     Document Type: Article

References (32)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 2005; 365: 1727-1741.
2. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
4. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-316.
5. Werner ER, Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T24 cell. J Biol Chem 1990; 265: 3189-3192.
6. Fuchs D, Milstien S, Kramer A, et al. Urinary neopterin concentrations vs total neopterin for clinical utility. Clin Chem 1989; 35: 2305-2307.
7. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006; 16: 240-252.
8. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15: 483-490.
9. Piccinini L, Zironi S, Federico M, Pini LA, Luppi G. Urinary neopterin in malignant lymphoma. Int J Biol Markers 1991; 6: 231-236.
10. Murr C, Berant A, Widschwendter M, Heim K, Schrocksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999; 45: 1998-2004.
11. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
12. Fuchs D, Hausen A, Reibnegger G, et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1991; 46: 65-70.
13. Denz H, Fuchs D, Huber H, et al. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 1990; 44: 186-189.
14. Wachter H, Artner-Dworzak E, Fuchs D, et al. Association between neopterin and iron metabolism in cancer patients. TumorDiagn Ther 1990; 11: 229-232.
15. Cermanova M, Melichar B, Solichova D, et al. Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis. Pteridines 2005; 16: 174-183.
16. Solichova D, Melichar B, Blaha V, et al. Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 34: 563-569.
17. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 2003; 95: 1165-1168.
18. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-1715.
19. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958-4965.
20. von Ingersleben G, Souchon R, Fitzner R. Serum neopterin levels in lung and breast cancer patients undergoing radiotherapy and/or chemotherapy. Int J Biol Markers 1988; 3: 135-139.
21. Muenchen HJ, Aggarwal SK. Activation of murine peritoneal macrophages after cisplatin and taxol combination. Anti-Cancer Drugs 1997; 8: 784-789.
22. Manthey CL, Perera PY, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994; 152: 825-831.
23. Hausen A, Fuchs D, Reibnegger G, Werner ER, Werner-Felmayer G, Wachter H. Reduction of ferric iron by 7, 8 - dihydronepterin. Pteridines 1990; 2: 83-85.
24. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811-6818.
25. Kearns CM, Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24 (Suppl 2): S2-91-S2-96.
26. Daga H, Isobe T, Miyazaki M, Fujitaka K, Kondo K, Kohno N. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: a clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer. Oncol Rep 2004; 11: 1225-1231.
27. Fujiwara K, Yamauchi H, Suzuki S, et al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 2001; 47: 22-26.
28. Pertussini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001; 97: 638-644.
29. Kaser A, Brandacher H, Steuer W, et al. Interleukin-6 stimulates trombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
30. Schuler M, Peschel C, Schneller F, et al. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res 1996; 16: 903-910.
31. Okada M, Sagawa T, Tominaga A, Kodama T, Hitsumoto Y. Two mechanisms for platelet-mediated killing of tumour cells: one cyclo-oxygenase dependent and the other nitric oxide dependent. Immunology 1996; 89: 158-164.
32. Brill A, Elinav H, Varon D. Differential role of platelet mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-235.